<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39135267</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>03</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1477-0377</ISSN><JournalIssue CitedMedium="Internet"><Volume>29</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Vascular medicine (London, England)</Title><ISOAbbreviation>Vasc Med</ISOAbbreviation></Journal><ArticleTitle>[S&#xed;ndrome post-tromboembolismo pulmonar, EPTEC, y HPTEC].</ArticleTitle><Pagination><StartPage>NP1</StartPage><EndPage>NP5</EndPage><MedlinePgn>NP1-NP5</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/1358863X241264222</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Porres-Aguilar</LastName><ForeName>Mateo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-2180-3000</Identifier><AffiliationInfo><Affiliation>Departamento de Medicina Interna, Divisiones de Medicina Hospitalaria y Trombosis Cl&#xed;nica del Adulto, Texas Tech University Health Sciences Center y Paul L. Foster School of Medicine, El Paso, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera-Lebron</LastName><ForeName>Belinda</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Divisi&#xf3;n de Medicina Pulmonar, Alergias y Cuidados Cr&#xed;ticos, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Nick H</ForeName><Initials>NH</Initials><AffiliationInfo><Affiliation>Divisi&#xf3;n de Medicina Pulmonar, Cuidados Intensivos y del Sue&#xf1;o, Universidad de California en San Diego, La Jolla, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Solomon</LastName><ForeName>Alexandra L</ForeName><Initials>AL</Initials><Identifier Source="ORCID">0000-0003-2363-886X</Identifier><AffiliationInfo><Affiliation>Eastern Vascular Associates, Danville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ratchford</LastName><ForeName>Elizabeth V</ForeName><Initials>EV</Initials><Identifier Source="ORCID">0000-0002-2244-5604</Identifier><AffiliationInfo><Affiliation>Centro Johns Hopkins de Medicina Vascular, Facultad de Medicina de la Universidad Johns Hopkins, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heresi</LastName><ForeName>Gustavo A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Departamento de Medicina Pulmonar y de Cuidados Cr&#xed;ticos, Instituto Respiratorio, Cl&#xed;nica Cleveland, Cleveland, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Vasc Med</MedlineTA><NlmUniqueID>9610930</NlmUniqueID><ISSNLinking>1358-863X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000925">Anticoagulants</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011655" MajorTopicYN="Y">Pulmonary Embolism</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000925" MajorTopicYN="N">Anticoagulants</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013577" MajorTopicYN="N">Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Hipertensi&#xf3;n pulmonar tromboemb&#xf3;lica cr&#xf3;nica (HPTEC)</Keyword><Keyword MajorTopicYN="N">enfermedad pulmonar tromboemb&#xf3;lica cr&#xf3;nica (EPTEC)</Keyword><Keyword MajorTopicYN="N">hipertensi&#xf3;n pulmonar (HP)</Keyword><Keyword MajorTopicYN="N">s&#xed;ndrome post-tromboembolismo pulmonar (post-TEP)</Keyword><Keyword MajorTopicYN="N">tromboembolismo pulmonar (TEP)</Keyword><Keyword MajorTopicYN="N">tromboembolismo venoso (TEV)</Keyword></KeywordList><CoiStatement>Declaraci&#xf3;n de intereses en conflictoLos autores declararon no tener potenciales conflictos de inter&#xe9;s con respecto a la investigaci&#xf3;n, autor&#xed;a y/o publicaci&#xf3;n de este manuscrito.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>13</Day><Hour>0</Hour><Minute>22</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39135267</ArticleId><ArticleId IdType="doi">10.1177/1358863X241264222</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38431048</PMID><DateCompleted><Year>2024</Year><Month>12</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2341-1929</ISSN><JournalIssue CitedMedium="Internet"><Volume>71</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Revista espanola de anestesiologia y reanimacion</Title><ISOAbbreviation>Rev Esp Anestesiol Reanim (Engl Ed)</ISOAbbreviation></Journal><ArticleTitle>Adult respiratory distress syndrome (ARDS) due to omeprazole-induced drug reaction with eosinophilia and systemic symptoms (DRESS): Case report and review of the literature.</ArticleTitle><Pagination><StartPage>763</StartPage><EndPage>770</EndPage><MedlinePgn>763-770</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.redare.2024.02.024</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2341-1929(24)00046-5</ELocationID><Abstract><AbstractText>Eosinophilia in not an uncommon findings in the intensive care unit (ICU); however, DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) syndrome, which is characterized by a hypersensitivity reaction to drugs and manifests as eosinophilia, systemic involvement and maculopapular erythematous rash 2-6 weeks after exposure to the offending drug, is an exceptional occurrence. We present the first case described in the literature of DRESS syndrome with pulmonary involvement in the form of interstitial pneumonitis and persistent adult respiratory distress syndrome (ARDS) secondary to proton pump inhibitors (PPI). The patient made a good recovery after withdrawal of the offending drug and long-term treatment with systemic corticosteroids. We also present a systematic review of all cases of DRESS with pulmonary involvement in the form of interstitial pneumonitis and cases of PPI-induced DRESS published to date; none of these describe pulmonary involvement.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024. Publicado por Elsevier Espa&#xf1;a, S.L.U.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D&#xed;az D&#xed;az</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Intensiva, Hospital Universitario Infanta Leonor, Madrid, Spain. Electronic address: domingodiazdiaz@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olmos Mata</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Interna, Hospital Cl&#xed;nico San Carlos, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palencia Herrej&#xf3;n</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Intensiva, Hospital Universitario Infanta Leonor, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez P&#xe9;rez</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Servicio de Medicina Intensiva, Hospital Universitario Infanta Leonor, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Esp Anestesiol Reanim (Engl Ed)</MedlineTA><NlmUniqueID>101778594</NlmUniqueID><ISSNLinking>2341-1929</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>KG60484QX9</RegistryNumber><NameOfSubstance UI="D009853">Omeprazole</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054328">Proton Pump Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009853" MajorTopicYN="Y">Omeprazole</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="Y">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063926" MajorTopicYN="Y">Drug Hypersensitivity Syndrome</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054328" MajorTopicYN="Y">Proton Pump Inhibitors</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult respiratory distress syndrome (ARDS)</Keyword><Keyword MajorTopicYN="N">DRESS syndrome</Keyword><Keyword MajorTopicYN="N">Eosinofilia</Keyword><Keyword MajorTopicYN="N">Eosinophilia</Keyword><Keyword MajorTopicYN="N">Fracaso multiorg&#xe1;nico</Keyword><Keyword MajorTopicYN="N">Interstitial pneumonitis</Keyword><Keyword MajorTopicYN="N">Multi-organ failure</Keyword><Keyword MajorTopicYN="N">Neumonitis intersticial</Keyword><Keyword MajorTopicYN="N">S&#xed;ndrome DRESS</Keyword><Keyword MajorTopicYN="N">S&#xed;ndrome de distress respiratorio del adulto (SDRA)</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>12</Month><Day>5</Day><Hour>5</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>3</Day><Hour>17</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>2</Day><Hour>19</Hour><Minute>15</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38431048</ArticleId><ArticleId IdType="doi">10.1016/j.redare.2024.02.024</ArticleId><ArticleId IdType="pii">S2341-1929(24)00046-5</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">33935292</PMID><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1578-1860</ISSN><JournalIssue CitedMedium="Internet"><Volume>222</Volume><Issue>4</Issue><PubDate><Year>2022</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Revista clinica espanola</Title><ISOAbbreviation>Rev Clin Esp</ISOAbbreviation></Journal><ArticleTitle>[Meta-analysis evaluating the risk of respiratory tract infections and acute respiratory distress syndrome with glucagon-like peptide-1 receptor agonists in cardiovascular outcome trials: Useful implications for the COVID-19 pandemic].</ArticleTitle><Pagination><StartPage>229</StartPage><EndPage>232</EndPage><MedlinePgn>229-232</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.rce.2021.04.001</ELocationID><Abstract><AbstractText>Patients with type 2 diabetes mellitus (T2DM) are at increased risk for severe coronavirus disease 2019 (COVID-19) and related mortality. Glucagon-like peptide-1 receptor agonists (GLP-1-RAs) have significant cardiovascular and renal benefits for patients with T2DM and related comorbidities. Their anti-inflammatory properties could be beneficial in these patients. This work provides less-biased estimates regarding the risk for respiratory tract infections and acute respiratory distress syndrome by performing the first significant meta-analysis of cardiovascular outcome trials in the literature. Notably, GLP-1-RAs do not seem to increase the risk for respiratory tract infection, pneumonia, or acute respiratory distress syndrome in patients with T2DM and cardiovascular comorbidities.</AbstractText><CopyrightInformation>&#xa9; 2021 Elsevier Espa&#xf1;a, S.L.U. and Sociedad Espa&#xf1;ola de Medicina Interna (SEMI). All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Patoulias</LastName><ForeName>D</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital &#xab;Hippokration&#xbb;, Thessaloniki, Grecia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boulmpou</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital &#xab;Hippokration&#xbb;, Thessaloniki, Grecia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imprialos</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital &#xab;Hippokration&#xbb;, Thessaloniki, Grecia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stavropoulos</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital &#xab;Hippokration&#xbb;, Thessaloniki, Grecia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papadopoulos</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Third Department of Cardiology, Aristotle University of Thessaloniki, General Hospital &#xab;Hippokration&#xbb;, Thessaloniki, Grecia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doumas</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Second Propedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, General Hospital &#xab;Hippokration&#xbb;, Thessaloniki, Grecia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Veterans Affairs Medical Center, George Washington University, Washington, District of Columbia, Columbia, EE. UU.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Metaan&#xe1;lisis para evaluar el riesgo de infecciones respiratorias y s&#xed;ndrome de distr&#xe9;s respiratorio del adulto con los agonistas del receptor del p&#xe9;ptido similar al glucag&#xf3;n tipo 1 en los ensayos de seguridad cardiovascular: consecuencias &#xfa;tiles para la pandemia de COVID-19.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Spain</Country><MedlineTA>Rev Clin Esp</MedlineTA><NlmUniqueID>8608576</NlmUniqueID><ISSNLinking>0014-2565</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="spa"><AbstractText>Los pacientes con diabetes mellitus tipo 2 (DMT2) presentan un mayor riesgo de experimentar una enfermedad grave por coronavirus 2019 (COVID-19) con un incremento de la mortalidad relacionada. Los agonistas del receptor del p&#xe9;ptido similar al glucag&#xf3;n tipo 1 (AR-GLP-1) ejercen efectos cardiovasculares y renales beneficiosos en los pacientes con DMT2 de alto riesgo cardiovascular. Sus propiedades antiinflamatorias podr&#xed;an resultar beneficiosas en estos pacientes. El presente estudio es un metaan&#xe1;lisis sobre el riesgo de infecci&#xf3;n respiratoria y distr&#xe9;s respiratorio del adulto causado por AR-GLP-1 utilizando como fuente los ensayos cl&#xed;nicos de seguridad cardiovascular publicados en la bibliograf&#xed;a. Hay que destacar que los AR-GLP-1 no parecen aumentar el riesgo de infecci&#xf3;n respiratoria, neumon&#xed;a ni s&#xed;ndrome de distr&#xe9;s respiratorio del adulto en los pacientes con DMT2 y alto riesgo cardiovascular.</AbstractText><CopyrightInformation>&#xa9; 2021 Elsevier Espa&#xf1;a, S.L.U. and Sociedad Espa&#xf1;ola de Medicina Interna (SEMI). All rights reserved.</CopyrightInformation></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Glucagon-like peptide-1 receptor agonists</Keyword><Keyword MajorTopicYN="N">Pneumonia</Keyword><Keyword MajorTopicYN="N">Respiratory infection</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes mellitus</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>3</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>4</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>27</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33935292</ArticleId><ArticleId IdType="pmc">PMC8075844</ArticleId><ArticleId IdType="doi">10.1016/j.rce.2021.04.001</ArticleId><ArticleId IdType="pii">S0014-2565(21)00102-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Barron E., Bakhai C., Kar P., Weaver A., Bradley D., Ismail H., et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: A whole-population study. Lancet Diabetes Endocrinol. 2020;8:813&#x2013;822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426088</ArticleId><ArticleId IdType="pubmed">32798472</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman N., Knighton P., Kar P., Kar P., O&#x2019;Keefe J., Curley., et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. Lancet Diabetes Endocrinol. 2020;8:823&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426091</ArticleId><ArticleId IdType="pubmed">32798471</ArticleId></ArticleIdList></Reference><Reference><Citation>Varikasuvu S.R., Dutt N., Thangappazham B., Varshney S. Diabetes and COVID-19: A pooled analysis related to disease severity and mortality. Prim Care Diabetes. 2021;15:24&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7456278</ArticleId><ArticleId IdType="pubmed">32891525</ArticleId></ArticleIdList></Reference><Reference><Citation>Buse J.B., Wexler D.J., Tsapas A., Rossing P., Mingrone G., Mathieu C., et al. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) Diabetes Care. 2020;43:487&#x2013;493. Erratum. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2020;43:487-493.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6971782</ArticleId><ArticleId IdType="pubmed">31857443</ArticleId></ArticleIdList></Reference><Reference><Citation>Bornstein S.R., Rubino F., Khunti K., Mingrone G., Hopkins D., Birkenfeld A.L., et al. Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes Endocrinol. 2020;8:546&#x2013;550.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7180013</ArticleId><ArticleId IdType="pubmed">32334646</ArticleId></ArticleIdList></Reference><Reference><Citation>Lisco G., de Tullio A., Giagulli V.A., Guastamacchia E., de Pergola G., Triggiani V. Hypothesized mechanisms explaining poor prognosis in type 2 diabetes patients with COVID-19: A review. Endocrine. 2020;70:441&#x2013;453.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417102</ArticleId><ArticleId IdType="pubmed">32779091</ArticleId></ArticleIdList></Reference><Reference><Citation>Longo M., Caruso P., Maiorino M.I., Bellastella G., Giugliano D., Esposito K. Treating type 2 diabetes in COVID-19 patients: The potential benefits of injective therapies. Cardiovasc Diabetol. 2020;19:115.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7375203</ArticleId><ArticleId IdType="pubmed">32698837</ArticleId></ArticleIdList></Reference><Reference><Citation>Dambha-Miller H., Albasri A., Hodgson S., Wilcox C.R., Khan S., Islam N., et al. Currently prescribed drugs in the UK that could upregulate or downregulate ACE2 in COVID-19 disease: A systematic review. BMJ Open. 2020;10:e040644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7490921</ArticleId><ArticleId IdType="pubmed">32928868</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso S.P., Daniels G.H., Brown-Frandsen K., Kristensen P., Mann J.F.E., Nauck M.A., et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4985288</ArticleId><ArticleId IdType="pubmed">27295427</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso S.P., Bain S.C., Consoli A., Eliaschewitz F.G., J&#xf3;dar E., Leiter L.A., et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834&#x2013;1844.</Citation><ArticleIdList><ArticleId IdType="pubmed">27633186</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein H.C., Colhoun H.M., Dagenais G.R., Diaz R., Lakchmanan M., Pais P., et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): A double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">31189511</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez A.F., Green J.B., Janmohamed S., D&#x2019;Agostino R.B., Sr., Granger C.B., Jones N.P., et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): A double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519&#x2013;1529.</Citation><ArticleIdList><ArticleId IdType="pubmed">30291013</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer M.A., Claggett B., Diaz R., Dickstein K., Gerstein H.C., K&#xf8;ber L.V., et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373:2247&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pubmed">26630143</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain M., Birkenfeld A.L., Donsmark M., Dungan K., Eliaschewitz F.G., Franco D.R., et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381:841&#x2013;851.</Citation><ArticleIdList><ArticleId IdType="pubmed">31185157</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman R.R., Bethel M.A., Mentz R.J., Thompson V.P., Lokhnygina Y., Buse J.B., et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377:1228&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9792409</ArticleId><ArticleId IdType="pubmed">28910237</ArticleId></ArticleIdList></Reference><Reference><Citation>Deeks JJ, Higgins JPT, Altman DG (2011) Chapter 9: Analyzing data and undertaking meta-analyses. In: Higgins JPT, Green S (eds) Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011], The Cochrane Collaboration.</Citation></Reference><Reference><Citation>Review Manager (RevMan) [Computer program] Version [5.3] Copenhagen: The Nordic Cochrane Centre TCC; 2014.</Citation></Reference><Reference><Citation>Higgins J.P.T., Sterne J.A.C., Savovi&#x107; J., Page M.J., Hr&#xf3;bjartsson A., Boutron I., et al. A revised tool for assessing risk of bias in randomized trials. Cochrane Database Syst Rev. 2016;10:29&#x2013;31.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33886853</PMID><DateCompleted><Year>2021</Year><Month>04</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1982-4335</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Season>Jan-Mar</Season></PubDate></JournalIssue><Title>Revista Brasileira de terapia intensiva</Title><ISOAbbreviation>Rev Bras Ter Intensiva</ISOAbbreviation></Journal><ArticleTitle>Consensus for the management of analgesia, sedation and delirium in adults with COVID-19-associated acute respiratory distress syndrome.</ArticleTitle><Pagination><StartPage>48</StartPage><EndPage>67</EndPage><MedlinePgn>48-67</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5935/0103-507X.20210005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0103-507X2021000100048</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To propose agile strategies for a comprehensive approach to analgesia, sedation, delirium, early mobility and family engagement for patients with COVID-19-associated acute respiratory distress syndrome, considering the high risk of infection among health workers, the humanitarian treatment that we must provide to patients and the inclusion of patients' families, in a context lacking specific therapeutic strategies against the virus globally available to date and a potential lack of health resources.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A nonsystematic review of the scientific evidence in the main bibliographic databases was carried out, together with national and international clinical experience and judgment. Finally, a consensus of recommendations was made among the members of the Committee for Analgesia, Sedation and Delirium of the Sociedad Argentina de Terapia Intensiva.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Recommendations were agreed upon, and tools were developed to ensure a comprehensive approach to analgesia, sedation, delirium, early mobility and family engagement for adult patients with acute respiratory distress syndrome due to COVID-19.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">Given the new order generated in intensive therapies due to the advancing COVID-19 pandemic, we propose to not leave aside the usual good practices but to adapt them to the particular context generated. Our consensus is supported by scientific evidence and national and international experience and will be an attractive consultation tool in intensive therapies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Donato</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-5949-3845</Identifier><AffiliationInfo><Affiliation>Hospital General de Agudos Jos&#xe9; Mar&#xed;a Penna - Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ministerio de Salud de la Naci&#xf3;n Argentina - Buenos Aires, Argentina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Instituto de Efectividad Cl&#xed;nica y Sanitaria - Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carini</LastName><ForeName>Federico Carlos</ForeName><Initials>FC</Initials><Identifier Source="ORCID">0000-0002-5196-4067</Identifier><AffiliationInfo><Affiliation>Hospital Italiano de Buenos Aires - Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meschini</LastName><ForeName>Mar&#xed;a Julia</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Hospital Interzonal General de Agudos General San Mart&#xed;n - La Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saubidet</LastName><ForeName>Ignacio L&#xf3;pez</ForeName><Initials>IL</Initials><Identifier Source="ORCID">0000-0002-0152-6536</Identifier><AffiliationInfo><Affiliation>Centro de Educaci&#xf3;n M&#xe9;dica e Investigaciones Cl&#xed;nicas "Norberto Quirno" - Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Adela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Sanatorio de La Trinidad Mitre - Buenos Aires, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarubio</LastName><ForeName>Marisol Garc&#xed;a</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Hospital Interzonal General de Agudos General San Mart&#xed;n - La Plata, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olmos</LastName><ForeName>Daniela</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Hospital Municipal Pr&#xed;ncipe de Asturias - C&#xf3;rdoba, Argentina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reina</LastName><ForeName>Rosa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Hospital Interzonal General de Agudos General San Mart&#xed;n - La Plata, Argentina.</Affiliation></AffiliationInfo></Author></AuthorList><Language>spa</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><VernacularTitle>Consenso para el manejo de la analgesia, sedaci&#xf3;n y delirium en adultos con s&#xed;ndrome de distr&#xe9;s respiratorio agudo por COVID-19.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Rev Bras Ter Intensiva</MedlineTA><NlmUniqueID>9506692</NlmUniqueID><ISSNLinking>0103-507X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000700">Analgesics</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000698" MajorTopicYN="N">Analgesia</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000700" MajorTopicYN="N">Analgesics</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057189" MajorTopicYN="N">Checklist</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D032921" MajorTopicYN="Y">Consensus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003693" MajorTopicYN="N">Delirium</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004434" MajorTopicYN="N">Early Ambulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005190" MajorTopicYN="N">Family</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007442" MajorTopicYN="N">Intubation, Intratracheal</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019148" MajorTopicYN="N">Neuromuscular Blockade</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059408" MajorTopicYN="N">Pain Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010147" MajorTopicYN="N">Pain Measurement</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011595" MajorTopicYN="N">Psychomotor Agitation</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="N">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">Proponer estrategias agile para este abordaje integral de la analgesia, sedaci&#xf3;n, delirium, implementaci&#xf3;n de movilidad temprana e inclusi&#xf3;n familiar del paciente con s&#xed;ndrome de dificultad respiratoria aguda por COVID-19, considerando el alto riesgo de infecci&#xf3;n que existe entre los trabajadores de salud, el tratamiento humanitario que debemos brindar al paciente y su familia, en un contexto de falta estrategias terap&#xe9;uticas espec&#xed;ficas contra el virus globalmente disponibles a la fecha y una potencial falta de recursos sanitarios.</AbstractText><AbstractText Label="METODOS" NlmCategory="METHODS">Se llev&#xf3; a cabo una revision no sistem&#xe1;tica de la evidencia cient&#xed;fica en las principales bases de datos bibliogr&#xe1;ficos, sumada a la experiencia y juicio cl&#xed;nico nacional e internacional. Finalmente, se realiz&#xf3; un consenso de recomendaciones entre los integrantes del Comit&#xe9; de Analgesia, Sedaci&#xf3;n y Delirium de la Sociedad Argentina de Terapia Intensiva.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Se acordaron recomendaciones y se desarrollaron herramientas para asegurar un abordaje integral de analgesia, sedaci&#xf3;n, delirium, implementaci&#xf3;n de movilidad temprana e inclusi&#xf3;n familiar del paciente adulto con s&#xed;ndrome de dificultad respiratoria aguda por COVID-19.</AbstractText><AbstractText Label="DISCUSI&#xd3;N" NlmCategory="UNASSIGNED">Ante el nuevo orden generado en las terapias intensivas por la progresi&#xf3;n de la pandemia de COVID-19, proponemos no dejar atr&#xe1;s las buenas pr&#xe1;cticas habituales, sino adaptarlas al contexto particular generado. Nuestro consenso est&#xe1; respaldado en la evidencia cient&#xed;fica, la experiencia nacional e internacional, y ser&#xe1; una herramienta de consulta atractiva en las terapias intensivas.</AbstractText></OtherAbstract><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="OBJETIVO">Proponer estrategias agile para este abordaje integral de la analgesia, sedaci&#xf3;n, <i>delirium,</i> implementaci&#xf3;n de movilidad temprana e inclusi&#xf3;n familiar del paciente con s&#xed;ndrome de dificultad respiratoria aguda por COVID-19, considerando el alto riesgo de infecci&#xf3;n que existe entre los trabajadores de salud, el tratamiento humanitario que debemos brindar al paciente y su familia, en un contexto de falta estrategias terap&#xe9;uticas espec&#xed;ficas contra el virus globalmente disponibles a la fecha y una potencial falta de recursos sanitarios.</AbstractText><AbstractText Label="METODOS">Se llev&#xf3; a cabo una revision no sistem&#xe1;tica de la evidencia cient&#xed;fica en las principales bases de datos bibliogr&#xe1;ficos, sumada a la experiencia y juicio cl&#xed;nico nacional e internacional. Finalmente, se realiz&#xf3; un consenso de recomendaciones entre los integrantes del Comit&#xe9; de Analgesia, Sedaci&#xf3;n y <i>Delirium</i> de la Sociedad Argentina de Terapia Intensiva.</AbstractText><AbstractText Label="RESULTADOS">Se acordaron recomendaciones y se desarrollaron herramientas para asegurar un abordaje integral de analgesia, sedaci&#xf3;n, <i>delirium,</i> implementaci&#xf3;n de movilidad temprana e inclusi&#xf3;n familiar del paciente adulto con s&#xed;ndrome de dificultad respiratoria aguda por COVID-19.</AbstractText><AbstractText Label="DISCUSI&#xd3;N">Ante el nuevo orden generado en las terapias intensivas por la progresi&#xf3;n de la pandemia de COVID-19, proponemos no dejar atr&#xe1;s las buenas pr&#xe1;cticas habituales, sino adaptarlas al contexto particular generado. Nuestro consenso est&#xe1; respaldado en la evidencia cient&#xed;fica, la experiencia nacional e internacional, y ser&#xe1; una herramienta de consulta atractiva en las terapias intensivas.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest:</b> None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>11</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>4</Month><Day>22</Day><Hour>17</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33886853</ArticleId><ArticleId IdType="pmc">PMC8075332</ArticleId><ArticleId IdType="doi">10.5935/0103-507X.20210005</ArticleId><ArticleId IdType="pii">S0103-507X2021000100048</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization (WHO)  Coronavirus disease (COVID-19) pandemic. 2020.  [2020 Nov 11].  Available from:  https://www.who.int/emergencies/diseases/novel-coronavirus-2019.</Citation></Reference><Reference><Citation>World Health Organization (WHO)  WHO Coronavirus Disease (COVID-19) Dashboard. 2020.  [2020 Nov 11].  Available from:  https://covid19.who.int/</Citation></Reference><Reference><Citation>Argentina. Ministerio de Salud  Nuevo coronavirus COVID-19. Jul, 2020.  [2020 Nov 11].  Informe diario. Available from:  https://www.argentina.gob.ar/coronavirus/informe-diario/julio2020.</Citation></Reference><Reference><Citation>Falavigna M, Colpani V, Stein C, Azevedo LC, Bagattini AM, Brito GV, et al. Diretrizes para o tratamento farmacol&#xf3;gico da COVID-19. Consenso da Associa&#xe7;&#xe3;o de Medicina Intensiva Brasileira, da Sociedade Brasileira de Infectologia e da Sociedade Brasileira de Pneumologia e Tisiologia. Rev Bras Ter Intensiva. 2020;32(2):166&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405746</ArticleId><ArticleId IdType="pubmed">32667444</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention  Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) 2020.  [2020 Nov 11].  Available from:  https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html.</Citation></Reference><Reference><Citation>Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118652</ArticleId><ArticleId IdType="pubmed">32362390</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahase E. Covid-19: most patients require mechanical ventilation in first 24 hours of critical care. BMJ. 2020;368:m1201&#x2013;m1201.</Citation><ArticleIdList><ArticleId IdType="pubmed">32209544</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72?314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020;133(9):1025&#x2013;1031.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147277</ArticleId><ArticleId IdType="pubmed">32044814</ArticleId></ArticleIdList></Reference><Reference><Citation>Young BE, Ong SW, Kalimuddin S, Low JG, Tan SY, Loh J, Ng OT, Marimuthu K, Ang LW, Mak TM, Lau SK, Anderson DE, Chan KS, Tan TY, Ng TY, Cui L, Said Z, Kurupatham L, Chen MI, Chan M, Vasoo S, Wang LF, Tan BH, Lin RTP, Lee VJ, Leo YS, Lye DC, Singapore 2019 Novel Coronavirus Outbreak Research Team Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7054855</ArticleId><ArticleId IdType="pubmed">32125362</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area. JAMA. 2020;323(20):2052&#x2013;2059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Argentina. Ministerio de Salud  Naci&#xf3;n invirti&#xf3; 42 mil millones de pesos en la expansi&#xf3;n del sistema de salud para responder a la pandemia de COVID-19.  [2020 Nov 11].  Available from:  https://www.argentina.gob.ar/noticias/nacion-invirtio-42-mil-millones-de-pesos-en-la-expansion-del-sistema-de-salud-para.</Citation></Reference><Reference><Citation>Ministerio de Salud de la Naci&#xf3;n  . An&#xe1;lisis de situaci&#xf3;n de salud: Republica Argentina. Ciudad Aut&#xf3;noma de Buenos Aires: Ministerio de Salud de la Naci&#xf3;n; 2018.  [2020 Nov 11].  Available from:  https://bancos.salud.gob.ar/sites/default/files/2019-12/0000001392cnt-anlisis_de_situacin_de_salud_-_repblica_argentina_-_asis_2018_compressed.pdf.</Citation></Reference><Reference><Citation>Marra A, Ely EW, Pandharipande PP, Patel MB. The ABCDEF Bundle in Critical Care. Crit Care Clin. 2017;33(2):225&#x2013;243.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5351776</ArticleId><ArticleId IdType="pubmed">28284292</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin JW, Skrobik Y, G&#xe9;linas C, Needham DM, Slooter AJC, Pandharipande PP, et al. Clinical Practice Guidelines for the Prevention and Management of Pain, Agitation/Sedation, Delirium, Immobility, and Sleep Disruption in Adult Patients in the ICU. Crit Care Med. 2018;46(9):e825&#x2013;e873.</Citation><ArticleIdList><ArticleId IdType="pubmed">30113379</ArticleId></ArticleIdList></Reference><Reference><Citation>Emanuel EJ, Persad G, Upshur R, Thome B, Parker M, Glickman A, et al. Fair allocation of scarce medical resources in the time of Covid-19. N Engl J Med. 2020;382(21):2049&#x2013;2055.</Citation><ArticleIdList><ArticleId IdType="pubmed">32202722</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wunsch H. Mechanical ventilation in COVID-19: interpreting the current epidemiology. Am J Respir Crit Care Med. 2020;202(1):1&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7328308</ArticleId><ArticleId IdType="pubmed">32402207</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Romieu AC, Adelman MW, Hockstein MA, Robichaux CJ, Edwards JA, Fazio JC, Blum JM, Jabaley CS, Caridi-Scheible M, Martin GS, Murphy DJ, Auld SC, Emory COVID-19 Quality and Clinical Research Collaborative Timing of intubation and mortality among critically ill coronavirus disease 2019 patients: a single-center cohort study. Crit Care Med. 2020;48(11):e1045&#x2013;e1053.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7448713</ArticleId><ArticleId IdType="pubmed">32804790</ArticleId></ArticleIdList></Reference><Reference><Citation>Argentina. Ministerio de Salud  Recomendaciones para el uso de los EPP. 2020.  [2020 Nov 11].  Available from:  https://www.sati.org.ar/images/MSN_19-03_EPP_Recomendaciones_uso_.pdf.</Citation></Reference><Reference><Citation>Argentina. Ministerio de Salud  Nuevo coronavirus COVID-19. Tratamiento de sost&#xe9;n.  [2020 Nov 11].  Available from: https://www.argentina.gob.ar/salud/coronavirus-COVID-19/tratamiento-sosten.</Citation></Reference><Reference><Citation>Carini F, Cassabella C, Garcia Sarubio M. Analgosedaci&#xf3;n en el paciente cr&#xed;tico en ventilaci&#xf3;n mec&#xe1;nica: el bundle ABCDEF en la pandemia de COVID-19. Rev Argentina Ter Intensiva. 2020;(Supl 1):47&#x2013;53.</Citation></Reference><Reference><Citation>Georgiou E, Paikousis L, Lambrinou E, Merkouris A, Papathanassoglou ED. The effectiveness of systematic pain assessment on critically ill patient outcomes: a randomised controlled trial. Aust Crit Care. 2020;33(5):412&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">31818632</ArticleId></ArticleIdList></Reference><Reference><Citation>Payen JF, Bru O, Bosson JL, Lagrasta A, Novel E, Deschaux I, et al. Assessing pain in critically ill sedated patients by using a behavioral pain scale. Crit Care Med. 2001;29(12):2258&#x2013;2263.</Citation><ArticleIdList><ArticleId IdType="pubmed">11801819</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xe9;linas C, Fillion L, Puntillo KA, Viens C, Fortier M. Validation of the critical-care pain observation tool in adult patients. Am J Crit Care. 2006;15(4):420&#x2013;427.</Citation><ArticleIdList><ArticleId IdType="pubmed">16823021</ArticleId></ArticleIdList></Reference><Reference><Citation>Markman JD, Gewandter JS, Frazer ME. Comparison of a pain tolerability question with the numeric rating scale for assessment of self-reported chronic pain. JAMA Netw Open. 2020;3(4):e203155.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7171555</ArticleId><ArticleId IdType="pubmed">32310281</ArticleId></ArticleIdList></Reference><Reference><Citation>Aitken LM, Bucknall T, Kent B, Mitchell M, Burmeister E, Keogh SJ, Cochrane Emergency and Critical Care Group Protocol-directed sedation versus non-protocol-directed sedation in mechanically ventilated intensive care adults and children. Cochrane Database Syst Rev. 2018;(11):CD009771&#x2013;CD009771.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6516800</ArticleId><ArticleId IdType="pubmed">30480753</ArticleId></ArticleIdList></Reference><Reference><Citation>Shehabi Y, Al-Bassam W, Pakavakis A, Murfin B, Howe B. Optimal sedation and pain management: a patient- and symptom-oriented paradigm. Semin Respir Crit Care Med. 2020 Sep 21;</Citation><ArticleIdList><ArticleId IdType="pubmed">32957139</ArticleId></ArticleIdList></Reference><Reference><Citation>Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O'Neal PV, Keane KA, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166(10):1338&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pubmed">12421743</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Truman B, Shintani A, Thomason JW, Wheeler AP, Gordon S, et al. Monitoring sedation status over time in ICU patients: reliability and validity of the Richmond Agitation-Sedation Scale (RASS) JAMA. 2003;289(22):2983&#x2013;2991.</Citation><ArticleIdList><ArticleId IdType="pubmed">12799407</ArticleId></ArticleIdList></Reference><Reference><Citation>International Consortium for EEG  Training of Anesthesia Practitioners (ICE-TAP) 2020.  [2020 Jul 10].  Available from:  https://icetap.org/</Citation></Reference><Reference><Citation>Riker RR, Picard JT, Fraser GL. Prospective evaluation of the Sedation-Agitation Scale for adult critically ill patients. Crit Care Med. 1999;27(7):1325&#x2013;1329.</Citation><ArticleIdList><ArticleId IdType="pubmed">10446827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouju P, Tadi&#xe9; JM, Barbarot N, Letheulle J, Uhel F, Fillatre P, et al. Clinical assessment and train-of-four measurements in critically ill patients treated with recommended doses of cisatracurium or atracurium for neuromuscular blockade: a prospective descriptive study. Ann Intensive Care. 2017;7(1):10&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5247382</ArticleId><ArticleId IdType="pubmed">28102521</ArticleId></ArticleIdList></Reference><Reference><Citation>Baumann MH, McAlpin BW, Brown K, Patel P, Ahmad I, Stewart R, et al. A prospective randomized comparison of train-of-four monitoring and clinical assessment during continuous ICU cisatracurium paralysis. Chest. 2004;126(4):1267&#x2013;1273.</Citation><ArticleIdList><ArticleId IdType="pubmed">15486392</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobi J, Fraser GL, Coursin DB, Riker RR, Fontaine D, Wittbrodt ET, Chalfin DB, Masica MF, Bjerke HS, Coplin WM, Crippen DW, Fuchs BD, Kelleher RM, Marik PE, Nasraway SA Jr, Murray MJ, Peruzzi WT, Lumb PD, Task Force of the American College of Critical Care Medicine of the Society of Critical Care Medicine.American Society of Health-System Pharmacists.American College of Chest Physicians Clinical practice guidelines for the sustained use of sedatives and analgesics in the critically ill adult. Crit Care Med. 2002;30(1):119&#x2013;141.</Citation><ArticleIdList><ArticleId IdType="pubmed">11902253</ArticleId></ArticleIdList></Reference><Reference><Citation>Haenggi M, Blum S, Brechbuehl R, Brunello A, Jakob SM, Takala J. Effect of sedation level on the prevalence of delirium when assessed with CAM-ICU and ICDSC. Intensive Care Med. 2013;39(12):2171&#x2013;2179.</Citation><ArticleIdList><ArticleId IdType="pubmed">23921976</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, et al. Delirium in mechanically ventilated patients: validity and reliability of the Confusion Assessment Method for the intensive care unit (CAM-ICU) JAMA. 2001;286(21):2703&#x2013;2710.</Citation><ArticleIdList><ArticleId IdType="pubmed">11730446</ArticleId></ArticleIdList></Reference><Reference><Citation>Critical Illness. Brain Dysfunction, and Survivorship (CIBS) Center  Confusion Assessment Method for the Intensive Care Unit (CAM-ICU) 2020.  [2020 Nov 11].  Available from:  https://www.icudelirium.org/medical-professionals/downloads/resources-by-category.</Citation></Reference><Reference><Citation>Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med. 2001;27(5):859&#x2013;864.</Citation><ArticleIdList><ArticleId IdType="pubmed">11430542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchison LC, O'Brien CE Changes in pharmacokinetics and pharmacodynamics in the elderly patient. J Pharm Pract. 2007;20(1):4&#x2013;12.</Citation></Reference><Reference><Citation>Montmeat D, Gard C, Raux M, Constantin JM, Tilleul P. Shortage of sedatives and neuromuscular blockers during COVID-19 pandemic: the result of an overstocking procedure in French hospitals? Anaesth Crit Care Pain Med. 2020;39(5):585&#x2013;586.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7326429</ArticleId><ArticleId IdType="pubmed">32654910</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr J, Fraser GL, Puntillo K, Ely EW, G&#xe9;linas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM, Coursin DB, Herr DL, Tung A, Robinson BR, Fontaine DK, Ramsay MA, Riker RR, Sessler CN, Pun B, Skrobik Y, Jaeschke R, American College of Critical Care Medicine Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263&#x2013;306.</Citation><ArticleIdList><ArticleId IdType="pubmed">23269131</ArticleId></ArticleIdList></Reference><Reference><Citation>Ammar MA, Sacha GL, Welch SC, Bass SN, Kane-Gill SL, Duggal A, et al. Sedation, analgesia, and paralysis in COVID-19 patients in the setting of drug shortages. J Intensive Care Med. 2021;36(2):157&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">32844730</ArticleId></ArticleIdList></Reference><Reference><Citation>University of Liverpool. COVID-19 Drug Interactions. 2020.  [2020 Jul 10].  Available from:  https://www.covid19-druginteractions.org/checker.</Citation></Reference><Reference><Citation>IBM Mcromedex.  [2020 Nov 11].  Available from:  www.micromedexsolutions.com.</Citation></Reference><Reference><Citation>Devlin JW, Roberts RJ. Pharmacology of commonly used analgesics and sedatives in the ICU: benzodiazepines, propofol, and opioids. Crit Care Clin. 2009;25(3):431-49, vii.</Citation><ArticleIdList><ArticleId IdType="pubmed">19576523</ArticleId></ArticleIdList></Reference><Reference><Citation>Muellejans B, L&#xf3;pez A, Cross MH, Bonome C, Morrison L, Kirkham AJT. Remifentanil versus fentanyl for analgesia based sedation to provide patient comfort in the intensive care unit: a randomized, double-blind controlled trial [ISRCTN43755713] Crit Care. 2004;8(1):R1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC420059</ArticleId><ArticleId IdType="pubmed">14975049</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu EHY, Tran DH, Lam SW, Irwin MG. Remifentanil tolerance and hyperalgesia: short-term gain, long-term pain? Anaesthesia. 2016;71(11):1347&#x2013;1362.</Citation><ArticleIdList><ArticleId IdType="pubmed">27734470</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler KE, Grilli R, Centofanti JE, Martin J, Gelinas C, Szumita PM, et al. Adjuvant analgesic use in the critically ill: a systematic review and meta-analysis. Crit Care Explor. 2020;2(7):e0157.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7340332</ArticleId><ArticleId IdType="pubmed">32696016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wanzuita R, Poli-de-Figueiredo LF, Pfuetzenreiter F, Cavalcanti AB, Westphal GA. Replacement of fentanyl infusion by enteral methadone decreases the weaning time from mechanical ventilation: a randomized controlled trial. Crit Care. 2012;16(2):R49&#x2013;R49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3681375</ArticleId><ArticleId IdType="pubmed">22420584</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatraju PK, Ghassemieh BJ, Nichols M, Kim R, Jerome KR, Nalla AK, et al. Covid-19 in critically ill patients in the Seattle Region - Case series. N Engl J Med. 2020;382(21):2012&#x2013;2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7143164</ArticleId><ArticleId IdType="pubmed">32227758</ArticleId></ArticleIdList></Reference><Reference><Citation>Gandhi RT. Large COVID-19 case series from the New York City Area. NEJM J Watch; Apr 29, 2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM-JW.NA51460</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, Du B, Li LJ, Zeng G, Yuen KY, Chen RC, Tang CL, Wang T, Chen PY, Xiang J, Li SY, Wang JL, Liang ZJ, Peng YX, Wei L, Liu Y, Hu YH, Peng P, Wang JM, Liu JY, Chen Z, Li G, Zheng ZJ, Qiu SQ, Luo J, Ye CJ, Zhu SY, Zhong NS, China Medical Treatment Expert Group for Covid-19 Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Shehabi Y, Walsh TS, Pandharipande PP, Ball JA, Spronk P, et al. Comfort and patient-centred care without excessive sedation: the eCASH concept. Intensive Care Med. 2016;42(6):962&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4846689</ArticleId><ArticleId IdType="pubmed">27075762</ArticleId></ArticleIdList></Reference><Reference><Citation>Shehabi Y, Chan L, Kadiman S, Alias A, Ismail WN, Tan MA, Khoo TM, Ali SB, Saman MA, Shaltut A, Tan CC, Yong CY, Bailey M, Sedation Practice in Intensive Care Evaluation Study Group investigators Sedation depth and long-term mortality in mechanically ventilated critically ill adults: a prospective longitudinal multicentre cohort study. Intensive Care Med. 2013;39(5):910&#x2013;918.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3625407</ArticleId><ArticleId IdType="pubmed">23344834</ArticleId></ArticleIdList></Reference><Reference><Citation>Kress JP, Pohlman AS, O'Connor MF, Hall JB. Daily interruption of sedative infusions in critically ill patients undergoing mechanical ventilation. N Engl J Med. 2000;342(20):1471&#x2013;1477.</Citation><ArticleIdList><ArticleId IdType="pubmed">10816184</ArticleId></ArticleIdList></Reference><Reference><Citation>Garber PM, Droege CA, Carter KE, Harger NJ, Mueller EW. Continuous infusion ketamine for adjunctive analgosedation in mechanically ventilated, critically ill patients. Pharmacotherapy. 2019;39(3):288&#x2013;296.</Citation><ArticleIdList><ArticleId IdType="pubmed">30746728</ArticleId></ArticleIdList></Reference><Reference><Citation>Grupo de Trabajo de Sedaci&#xf3;n, Analg&#xe9;sia y Delirium de Sociedad Espa&#xf1;ola de Medicina Intensiva, Cr&#xed;tica y Unidades Coronrias (SEMICYUC)  Protocolos de analgosedaci&#xf3;n en pacientes con infecci&#xf3;n por SARS-CoV-2 (COVID-19) en caso de desabastecimiento. 2020.  [2020 Nov 11].  Available from:  https://semicyuc.org/wp-content/uploads/2020/03/PROTOCOLO-ANALGOSED-COVID-SEMICYUC.pdf.</Citation></Reference><Reference><Citation>Manasco AT, Stephens RJ, Yaeger LH, Roberts BW, Fuller BM. Ketamine sedation in mechanically ventilated patients: a systematic review and meta-analysis. J Crit Care. 2020;56:80&#x2013;88.</Citation><ArticleIdList><ArticleId IdType="pubmed">31865256</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y, Jin X, Kang Y, Liang G, Liu T, Deng N. Midazolam and propofol used alone or sequentially for long-term sedation in critically ill, mechanically ventilated patients: a prospective, randomized study. Crit Care. 2014;18(3):R122&#x2013;R122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4095601</ArticleId><ArticleId IdType="pubmed">24935517</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H, Wang C, Wang Y, Tong H, Feng Y, Li M, et al. Sedative drugs used for mechanically ventilated patients in intensive care units: a systematic review and network meta-analysis. Curr Med Res Opin. 2019;35(3):435&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">30086671</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Guen M, Liu N, Tounou F, Aug&#xe9; M, Tuil O, Chazot T, et al. Dexmedetomidine reduces propofol and remifentanil requirements during bispectral index-guided closed-loop anesthesia: a double-blind, placebo-controlled trial. Anesth Analg. 2014;118(5):946&#x2013;955.</Citation><ArticleIdList><ArticleId IdType="pubmed">24722260</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia ZQ, Chen SQ, Yao X, Xie CB, Wen SH, Liu KX. Clinical benefits of dexmedetomidine versus propofol in adult intensive care unit patients: a meta-analysis of randomized clinical trials. J Surg Res. 2013;185(2):833&#x2013;843.</Citation><ArticleIdList><ArticleId IdType="pubmed">23910886</ArticleId></ArticleIdList></Reference><Reference><Citation>Conti G, Ranieri VM, Costa R, Garratt C, Wighton A, Spinazzola G, et al. Effects of dexmedetomidine and propofol on patient-ventilator interaction in difficult-to-wean, mechanically ventilated patients: a prospective, open-label, randomised, multicentre study. Crit Care. 2016;20(1):206&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4930611</ArticleId><ArticleId IdType="pubmed">27368279</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruickshank M, Henderson L, MacLennan G, Fraser C, Campbell M, Blackwood B, et al. Alpha-2 agonists for sedation of mechanically ventilated adults in intensive care units: a systematic review. Health Technol Assess. 2016;20(25):v&#x2013;xx.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4828957</ArticleId><ArticleId IdType="pubmed">27035758</ArticleId></ArticleIdList></Reference><Reference><Citation>Terry K, Blum R, Szumita P. Evaluating the transition from dexmedetomidine to clonidine for agitation management in the intensive care unit. SAGE Open Med. 2015;3:2050312115621767&#x2013;2050312115621767.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4821213</ArticleId><ArticleId IdType="pubmed">27092265</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnon DJ, Riker RR, Glisic EK, Kelner A, Perrey HM, Fraser GL. Transition from dexmedetomidine to enteral clonidine for ICU sedation: an observational pilot study. Pharmacotherapy. 2015;35(3):251&#x2013;259.</Citation><ArticleIdList><ArticleId IdType="pubmed">25809176</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang JG, Belley-Cot&#xe9; E, Burry L, Duffett M, Karachi T, Perri D, et al. Clonidine for sedation in the critically ill: a systematic review and meta-analysis. Crit Care. 2017;21(1):75&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5363026</ArticleId><ArticleId IdType="pubmed">28330506</ArticleId></ArticleIdList></Reference><Reference><Citation>Mion G. Ketamine infusions for sedation in ICU. Anaesth Crit Care Pain Med. 2019;38(4):397&#x2013;398.</Citation><ArticleIdList><ArticleId IdType="pubmed">30562616</ArticleId></ArticleIdList></Reference><Reference><Citation>Groetzinger LM, Rivosecchi RM, Bain W, Bahr M, Chin K, McVerry BJ, et al. Ketamine infusion for adjunct sedation in mechanically ventilated adults. Pharmacotherapy. 2018;38(2):181&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">29193185</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin JW, O'Neal HR Jr, Thomas C., Barnes Daly MA., Stollings JL., Janz DR, et al. Strategies to Optimize ICU Liberation (A to F) Bundle Performance in Critically Ill Adults With Coronavirus Disease 2019. Crit Care Explor. 2020;2(6):e0139.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314345</ArticleId><ArticleId IdType="pubmed">32696002</ArticleId></ArticleIdList></Reference><Reference><Citation>Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al. Clinical practice guidelines for the management of atopic dermatitis 2018. J Dermatol. 2019;46(12):1053&#x2013;1101.</Citation><ArticleIdList><ArticleId IdType="pubmed">31599013</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenberg SB, Vender J. The use of neuromuscular blocking agents in the ICU: where are we now? Crit Care Med. 2013;41(5):1332&#x2013;1344.</Citation><ArticleIdList><ArticleId IdType="pubmed">23591211</ArticleId></ArticleIdList></Reference><Reference><Citation>Papazian L, Forel JM, Gacouin A, Penot-Ragon C, Perrin G, Loundou A, Jaber S, Arnal JM, Perez D, Seghboyan JM, Constantin JM, Courant P, Lefrant JY, Gu&#xe9;rin C, Prat G, Morange S, Roch A, ACURASYS Study Investigators Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107&#x2013;1116.</Citation><ArticleIdList><ArticleId IdType="pubmed">20843245</ArticleId></ArticleIdList></Reference><Reference><Citation>National Heart, Lung, and Blood Institute PETAL Clinical Trials Network. Moss M, Huang DT, Brower RG, Ferguson ND, Ginde AA, Gong MN, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997&#x2013;2008.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6741345</ArticleId><ArticleId IdType="pubmed">31112383</ArticleId></ArticleIdList></Reference><Reference><Citation>deBacker J, Hart N, Fan E. Neuromuscular Blockade in the 21st Century Management of the Critically Ill Patient. Chest. 2017;151(3):697&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">27818334</ArticleId></ArticleIdList></Reference><Reference><Citation>Alhazzani W, M&#xf8;ller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: Guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19) Intensive Care Med. 2020;46(5):854&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101866</ArticleId><ArticleId IdType="pubmed">32222812</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore L, Kramer CJ, Delcoix-Lopes S, Modrykamien AM. Comparison of cisatracurium versus atracurium in early ARDS. Respir Care. 2017;62(7):947&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pubmed">28351905</ArticleId></ArticleIdList></Reference><Reference><Citation>Aung Thein MZ, Pereira J V, Nitchingham A, Caplan GA. A call to action for delirium research: meta-analysis and regression of delirium associated mortality. BMC Geriatr. 2020;20(1):325&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7487610</ArticleId><ArticleId IdType="pubmed">32894065</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcez FB, Aliberti MJ, Poco PC, Hiratsuka M, Takahashi SF, Coelho VA, et al. Delirium and adverse outcomes in hospitalized patients with COVID-19. J Am Geriatr Soc. 2020;68(11):2440&#x2013;2446.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7460960</ArticleId><ArticleId IdType="pubmed">32835425</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan SH, Lindroth H, Perkins AJ, Yasser J, Wang S, Roberts S, et al. Delirium Incidence, Duration and Severity in Critically Ill Patients with COVID-19. Crit Care Explor. 2020;2(12):e0290.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7690767</ArticleId><ArticleId IdType="pubmed">33251519</ArticleId></ArticleIdList></Reference><Reference><Citation>Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russell CD, Dunning J, Openshaw PJ, Baillie JK, Semple MG, ISARIC4C investigators Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985&#x2013;m1985.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243036</ArticleId><ArticleId IdType="pubmed">32444460</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotfis K, Williams Roberson S, Wilson JE, Dabrowski W, Pun BT, Ely EW. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Crit Care. 2020;24(1):176&#x2013;176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7186945</ArticleId><ArticleId IdType="pubmed">32345343</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos E, Cardoso D, Neves H, Cunha M, Rodrigues M, Ap&#xf3;stolo J. Effectiveness of haloperidol prophylaxis in critically ill patients with a high risk of delirium: a systematic review. JBI Database Syst Rev Implement Rep. 2017;15(5):1440&#x2013;1472.</Citation><ArticleIdList><ArticleId IdType="pubmed">28498176</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrijver EJ, de Graaf K, de Vries OJ, Maier AB, Nanayakkara PW. Efficacy and safety of haloperidol for in-hospital delirium prevention and treatment: a systematic review of current evidence. Eur J Intern Med. 2016;27:14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">26553001</ArticleId></ArticleIdList></Reference><Reference><Citation>Girard TD, Exline MC, Carson SS, Hough CL, Rock P, Gong MN, Douglas IS, Malhotra A, Owens RL, Feinstein DJ, Khan B, Pisani MA, Hyzy RC, Schmidt GA, Schweickert WD, Hite RD, Bowton DL, Masica AL, Thompson JL, Chandrasekhar R, Pun BT, Strength C, Boehm LM, Jackson JC, Pandharipande PP, Brummel NE, Hughes CG, Patel MB, Stollings JL, Bernard GR, Dittus RS, Ely EW, MIND-USA Investigators Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2018;379(26):2506&#x2013;2516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6364999</ArticleId><ArticleId IdType="pubmed">30346242</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi M, Barra ME, Newman K, Sin JH. Safety and effectiveness of intravenous chlorpromazine for agitation in critically ill patients. J Intensive Care Med. 2018;35(10):1118&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">30558470</ArticleId></ArticleIdList></Reference><Reference><Citation>Herling SF, Greve IE, Vasilevskis EE, Egerod I, Bekker Mortensen C, Moller AM, et al. Interventions for preventing intensive care unit delirium in adults. Cochrane Database Syst Rev. 2018;11(11):CD009783&#x2013;CD009783.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6373634</ArticleId><ArticleId IdType="pubmed">30484283</ArticleId></ArticleIdList></Reference><Reference><Citation>Burry L, Hutton B, Williamson DR, Mehta S, Adhikari NK, Cheng W, et al. Pharmacological interventions for the treatment of delirium in critically ill adults. Cochrane Database Syst Rev. 2019;9(9):CD011749&#x2013;CD011749.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6719921</ArticleId><ArticleId IdType="pubmed">31479532</ArticleId></ArticleIdList></Reference><Reference><Citation>Pandharipande PP, Sanders RD, Girard TD, McGrane S, Thompson JL, Shintani AK, Herr DL, Maze M, Ely EW, MENDS investigators Effect of dexmedetomidine versus lorazepam on outcome in patients with sepsis: an a priori-designed analysis of the MENDS randomized controlled trial. Crit Care. 2010;14(2):R38&#x2013;R38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887145</ArticleId><ArticleId IdType="pubmed">20233428</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakob SM, Ruokonen E, Grounds RM, Sarapohja T, Garratt C, Pocock SJ, Bratty JR, Takala J, Dexmedetomidine for Long-Term Sedation Investigators Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012;307(11):1151&#x2013;1160.</Citation><ArticleIdList><ArticleId IdType="pubmed">22436955</ArticleId></ArticleIdList></Reference><Reference><Citation>Reade MC, O&#x2019;Sullivan K, Bates S, Goldsmith D, Ainslie WR, Bellomo R. Dexmedetomidine vs. haloperidol in delirious, agitated, intubated patients: a randomised open-label trial. Crit Care. 2009;13(3):R75&#x2013;R75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2717438</ArticleId><ArticleId IdType="pubmed">19454032</ArticleId></ArticleIdList></Reference><Reference><Citation>Pun BT, Balas MC, Barnes-Daly MA, Thompson JL, Aldrich JM, Barr J, et al. Caring for Critically Ill Patients with the ABCDEF Bundle: Results of the ICU Liberation Collaborative in Over 15,000 Adults. Crit Care Med. 2019;47(1):3&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6298815</ArticleId><ArticleId IdType="pubmed">30339549</ArticleId></ArticleIdList></Reference><Reference><Citation>HealthManagement.org  COVID-19 Pandemic: Lessons from Italy. 2020.  [2020 Jul 10].  Available from:  https://healthmanagement.org/c/icu/news/covid-19-pandemic-lessons-from-italy.</Citation></Reference><Reference><Citation>Hodgson CL, Stiller K, Needham DM, Tipping CJ, Harrold M, Baldwin CE, et al. Expert consensus and recommendations on safety criteria for active mobilization of mechanically ventilated critically ill adults. Crit Care Med. 2014;18(6):658&#x2013;658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4301888</ArticleId><ArticleId IdType="pubmed">25475522</ArticleId></ArticleIdList></Reference><Reference><Citation>Schweickert WD, Pohlman MC, Pohlman AS, Nigos C, Pawlik AJ, Esbrook CL, et al. Early physical and occupational therapy in mechanically ventilated, critically ill patients: a randomised controlled trial. Lancet. 2009;373(9678):1874&#x2013;1882.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906655</ArticleId><ArticleId IdType="pubmed">19446324</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely EW. The ABCDEF bundle: science and philosophy of how ICU liberation serves patients and families. Crit Care Med. 2017;45(2):321&#x2013;330.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830123</ArticleId><ArticleId IdType="pubmed">28098628</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa RG, Falavigna M, da Silva DB, Sganzerla D, Santos MMS, Kochhann R, de Moura RM, Eug&#xea;nio CS, Haack TDSR, Barbosa MG, Robinson CC, Schneider D, de Oliveira DM, Jeffman RW, Cavalcanti AB, Machado FR, Azevedo LCP, Salluh JIF, Pellegrini JAS, Moraes RB, Foernges RB, Torelly AP, Ayres LO, Duarte PAD, Lovato WJ, Sampaio PHS, de Oliveira J&#xfa;nior LC, Paranhos JLDR, Dantas ADS, de Brito PIPGG, Paulo EAP, Gallindo MAC, Pilau J, Valentim HM, Meira Teles JM, Nobre V, Birriel DC, Corr&#xea;a E, Castro L, Specht AM, Medeiros GS, Tonietto TF, Mesquita EC, da Silva NB, Korte JE, Hammes LS, Giannini A, Bozza FA, Teixeira CICU, Visits Study Group Investigators. Brazilian Research in Intensive Care Network Effect of flexible family visitation on delirium among patients in the intensive care unit: the ICU visits randomized clinical trial. JAMA. 2019;322(3):216&#x2013;228.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6635909</ArticleId><ArticleId IdType="pubmed">31310297</ArticleId></ArticleIdList></Reference><Reference><Citation>Argentina. Senado y C&#xe1;mara de Diputados de la Naci&#xf3;n Argentina  Ley 27.553. Boletin Oficial de la Rep&#xfa;blica Argentina. 11/08/2020.  [2020 Nov 11].  Available from:  https://www.boletinoficial.gob.ar/detalleAviso/primera/233439/20200811.</Citation></Reference><Reference><Citation>Ballesteros Sanz MA, Hern&#xe1;ndez-Tejedor A, Estella A, Jim&#xe9;nes Rivera JJ, Gonz&#xe1;les de Molina Ortiz FJ, Sandiumenge Camps A, et al. Recomendaciones de "hacer" y "no hacer" en el tratamiento de los pacientes cr&#xed;ticos ante la pandemia por coronavirus causante de COVID-19 de los Grupos de Trabajo de la Sociedad Espa&#xf1;ola de Medicina Intensiva, Cr&#xed;tica y Unidades Coronarias (SEMICYUC) Med Intensiva. 2020;44(6):371&#x2013;388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7142677</ArticleId><ArticleId IdType="pubmed">32360034</ArticleId></ArticleIdList></Reference><Reference><Citation>Celis-Rodr&#xed;guez E, Birchenall C, de la Cal MA, Castorena Arellano G, Hern&#xe1;ndez A, Ceraso D, et al. Gu&#xed;a de pr&#xe1;ctica cl&#xed;nica basada en la evidencia para el manejo de la sedoanalgesia en el paciente adulto cr&#xed;ticamente enfermo. Med Intensiva. 2013;37(8):519&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pubmed">17988592</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson JE, Harvey MA, Bemis-Dougherty A, Smith JM, Hopkins RO. Implementation of the Pain, Agitation, and Delirium Clinical Practice Guidelines and promoting patient mobility to prevent post-intensive care syndrome. Crit Care Med. 2013;41(9) Suppl 1:S136&#x2013;S145.</Citation><ArticleIdList><ArticleId IdType="pubmed">23989091</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31967231</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1982-4335</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2019</Year><Season>Oct-Dec</Season></PubDate></JournalIssue><Title>Revista Brasileira de terapia intensiva</Title><ISOAbbreviation>Rev Bras Ter Intensiva</ISOAbbreviation></Journal><ArticleTitle>Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome in adult patients: a systematic review and meta-analysis.</ArticleTitle><Pagination><StartPage>548</StartPage><EndPage>554</EndPage><MedlinePgn>548-554</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.5935/0103-507X.20190077</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0103-507X2019000400548</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The evidence of improved survival with the use of extracorporeal membrane oxygenation (ECMO) in acute respiratory distress syndrome is still uncertain.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This systematic review and meta-analysis was registered in the PROSPERO database with the number CRD-42018098618. We performed a structured search of Medline, Lilacs, and ScienceDirect for randomized controlled trials evaluating the use of ECMO associated with (ultra)protective mechanical ventilation for severe acute respiratory failure in adult patients. We used the Cochrane risk of bias tool to evaluate the quality of the evidence. Our primary objective was to evaluate the effect of ECMO on the last reported mortality. Secondary outcomes were treatment failure, hospital length of stay and the need for renal replacement therapy in both groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Two randomized controlled studies were included in the meta-analysis, comprising 429 patients, of whom 214 were supported with ECMO. The most common reason for acute respiratory failure was pneumonia (60% - 65%). Respiratory ECMO support was associated with a reduction in last reported mortality and treatment failure with risk ratios (RR: 0.76; 95%CI 0.61 - 0.95 and RR: 0.68; 95%CI 0.55 - 0.85, respectively). Extracorporeal membrane oxygenation reduced the need for renal replacement therapy, with a RR of 0.88 (95%CI 0.77 - 0.99). Intensive care unit and hospital lengths of stay were longer in ECMO-supported patients, with an additional P50th 14.84 (P25th - P75th: 12.49 - 17.18) and P50th 29.80 (P25th - P75th: 26.04 - 33.56] days, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Respiratory ECMO support in severe acute respiratory distress syndrome patients is associated with a reduced mortality rate and a reduced need for renal replacement therapy but a substantial increase in the lengths of stay in the intensive care unit and hospital. Our results may help bedside decision-making regarding ECMO initiation in patients with severe respiratory distress syndrome.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendes</LastName><ForeName>Pedro Vitale</ForeName><Initials>PV</Initials><AffiliationInfo><Affiliation>Unidade de Terapia Intensiva, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo - S&#xe3;o Paulo (SP), Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melro</LastName><ForeName>Livia Maria Garcia</ForeName><Initials>LMG</Initials><AffiliationInfo><Affiliation>Unidade de Terapia Intensiva, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo - S&#xe3;o Paulo (SP), Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ho Yeh</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Unidade de Terapia Intensiva, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo - S&#xe3;o Paulo (SP), Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joelsons</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0003-4190-1334</Identifier><AffiliationInfo><Affiliation>Unidade de Terapia Intensiva, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo - S&#xe3;o Paulo (SP), Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zigaib</LastName><ForeName>Rogerio</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Unidade de Terapia Intensiva, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo - S&#xe3;o Paulo (SP), Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ribeiro</LastName><ForeName>Jos&#xe9; Mauro da Fonseca Pestana</ForeName><Initials>JMDFP</Initials><AffiliationInfo><Affiliation>Unidade de Terapia Intensiva, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo - S&#xe3;o Paulo (SP), Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Besen</LastName><ForeName>Bruno Adler Maccagnan Pinheiro</ForeName><Initials>BAMP</Initials><Identifier Source="ORCID">0000-0002-3516-9696</Identifier><AffiliationInfo><Affiliation>Unidade de Terapia Intensiva, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo - S&#xe3;o Paulo (SP), Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Marcelo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Unidade de Terapia Intensiva, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo - S&#xe3;o Paulo (SP), Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>por</Language><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><VernacularTitle>Oxigena&#xe7;&#xe3;o por membrana extracorp&#xf3;rea para s&#xed;ndrome do desconforto respirat&#xf3;rio agudo grave em pacientes adultos: revis&#xe3;o sistem&#xe1;tica e metan&#xe1;lise.</VernacularTitle></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Rev Bras Ter Intensiva</MedlineTA><NlmUniqueID>9506692</NlmUniqueID><ISSNLinking>0103-507X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015199" MajorTopicYN="N">Extracorporeal Membrane Oxygenation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="OBJETIVO" NlmCategory="OBJECTIVE">A evid&#xea;ncia de melhora da sobreviv&#xea;ncia com uso de oxigena&#xe7;&#xe3;o por membrana extracorp&#xf3;rea na s&#xed;ndrome do desconforto respirat&#xf3;rio agudo ainda permanece incerta.</AbstractText><AbstractText Label="M&#xc9;TODOS" NlmCategory="UNASSIGNED">Esta revis&#xe3;o sistem&#xe1;tica e metan&#xe1;lise foi registrada na base de dados PROSPERO com o n&#xfa;mero CRD-42018098618. Conduzimos uma busca estruturada nas bases Medline, LILACS e ScienceDirect visando a ensaios randomizados e controlados que tivessem avaliado o uso de oxigena&#xe7;&#xe3;o por membrana extracorp&#xf3;rea associada com ventila&#xe7;&#xe3;o mec&#xe2;nica (ultra)protetora em pacientes adultos com s&#xed;ndrome do desconforto respirat&#xf3;rio agudo grave. Utilizamos a ferramenta de riscos de vi&#xe9;s da Cochrane para avaliar a qualidade da evid&#xea;ncia. O desfecho prim&#xe1;rio consistiu em avaliar o efeito do uso oxigena&#xe7;&#xe3;o por membrana extracorp&#xf3;rea no &#xfa;ltimo relato de mortalidade. Os desfechos secund&#xe1;rios foram: falha terap&#xea;utica, tempo de perman&#xea;ncia no hospital e necessidade de terapia de substitui&#xe7;&#xe3;o renal em ambos os grupos.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="RESULTS">Inclu&#xed;ram-se na metan&#xe1;lise dois ensaios randomizados e controlados, compreendendo 429 pacientes, dos quais 214 receberam suporte respirat&#xf3;rio extracorp&#xf3;reo. A raz&#xe3;o mais comum para a insufici&#xea;ncia respirat&#xf3;ria foi pneumonia (60% - 65%). O suporte respirat&#xf3;rio com oxigena&#xe7;&#xe3;o por membrana extracorp&#xf3;rea foi associado a uma redu&#xe7;&#xe3;o na mortalidade e redu&#xe7;&#xe3;o em falha terap&#xea;utica com taxas de risco (RR: 0,76; IC95% 0,61 - 0,95; RR: 0,68; IC95% 0,55 - 0,85, respectivamente). O uso de oxigena&#xe7;&#xe3;o por membrana extracorp&#xf3;rea reduziu a necessidade de terapia de substitui&#xe7;&#xe3;o renal com uma RR de 0,88 (IC95% 0,77 - 0,99). O tempo de perman&#xea;ncia na unidade de terapia intensiva e no hospital foram maiores no grupo de pacientes que recebeu suporte com oxigena&#xe7;&#xe3;o por membrana extracorp&#xf3;rea, com acr&#xe9;scimo de 14,84 (P25&#xb0;-P75&#xb0;: 12,49 - 17,18) e 29,80 (P25&#xb0;- P75&#xb0;: 26,04 - 33,56) dias, respectivamente.</AbstractText><AbstractText Label="CONCLUS&#xc3;O" NlmCategory="UNASSIGNED">O suporte com oxigena&#xe7;&#xe3;o por membrana extracorp&#xf3;rea na s&#xed;ndrome do desconforto respirat&#xf3;rio agudo grave est&#xe1; associado a uma redu&#xe7;&#xe3;o da taxa de mortalidade e da necessidade de terapia de substitui&#xe7;&#xe3;o renal, por&#xe9;m apresenta aumento substancial no tempo de perman&#xea;ncia na unidade de terapia intensiva e no hospital. Nossos resultados podem ajudar no processo decis&#xf3;rio junto ao leito quanto ao in&#xed;cio do suporte com oxigena&#xe7;&#xe3;o por membrana extracorp&#xf3;rea na s&#xed;ndrome do desconforto respirat&#xf3;rio agudo grave.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest:</b> None.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2019</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31967231</ArticleId><ArticleId IdType="pmc">PMC7008998</ArticleId><ArticleId IdType="doi">10.5935/0103-507X.20190077</ArticleId><ArticleId IdType="pii">S0103-507X2019000400548</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators. Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N, et al. Extracorporeal membrane oxygenation for 2009 influenza A(H1N1) acute respiratory distress syndrome. JAMA. 2009;302(17):1888&#x2013;1895.</Citation><ArticleIdList><ArticleId IdType="pubmed">19822628</ArticleId></ArticleIdList></Reference><Reference><Citation>Noah MA, Peek GJ, Finney SJ, Griffiths MJ, Harrison DA, Grieve R, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1) JAMA. 2011;306(15):1659&#x2013;1668.</Citation><ArticleIdList><ArticleId IdType="pubmed">21976615</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham T, Combes A, Roz&#xe9; H, Chevret S, Mercat A, Roch A, Mourvillier B, Ara-Somohano C, Bastien O, Zogheib E, Clavel M, Constan A, Marie Richard JC, Brun-Buisson C, Brochard L, REVA Research Network Extracorporeal membrane oxygenation for pandemic influenza A(H1N1) induced acute respiratory distress syndrome. A cohort study and propensity-matched analysis. Am J Respir Crit Care Med. 2012;187(3):276&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">23155145</ArticleId></ArticleIdList></Reference><Reference><Citation>Lind&#xe9;n V, Palm&#xe9;r K, Reinhard J, Westman R, Ehr&#xe9;n H, Granholm T, et al. High survival in adult patients with acute respiratory distress syndrome treated by extracorporeal membrane oxygenation, minimal sedation, and pressure supported ventilation. Intensive Care Med. 2000;26(11):1630&#x2013;1637.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094942</ArticleId><ArticleId IdType="pubmed">11193269</ArticleId></ArticleIdList></Reference><Reference><Citation>Park M, Azevedo LC, Mendes PV, Carvalho CR, Amato MB, Schettino GP, et al. First-year experience of a Brazilian tertiary medical center in supporting severely ill patients using extracorporeal membrane oxygenation. Clinics (Sao Paulo) 2012;67(10):1157&#x2013;1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3460018</ArticleId><ArticleId IdType="pubmed">23070342</ArticleId></ArticleIdList></Reference><Reference><Citation>Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, Hibbert CL, Truesdale A, Clemens F, Cooper N, Firmin RK, Elbourne D, CESAR trial collaboration Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009;374(9698):1351&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">19762075</ArticleId></ArticleIdList></Reference><Reference><Citation>Zampieri FG, Mendes PV, Ranzani OT, Taniguchi LU, Pontes Azevedo LC, Vieira Costa EL, et al. Extracorporeal membrane oxygenation for severe respiratory failure in adult patients: a systematic review and meta-analysis of current evidence. J Crit Care. 2013;28(6):998&#x2013;1005.</Citation><ArticleIdList><ArticleId IdType="pubmed">23954453</ArticleId></ArticleIdList></Reference><Reference><Citation>Zangrillo A, Biondi-Zoccai G, Landoni G, Frati G, Patroniti N, Pesenti A, et al. Extracorporeal membrane oxygenation (ECMO) in patients with H1N1 influenza infection: a systematic review and meta-analysis including 8 studies and 266 patients receiving ECMO. Crit Care. 2013;17(1):R30&#x2013;R30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4057025</ArticleId><ArticleId IdType="pubmed">23406535</ArticleId></ArticleIdList></Reference><Reference><Citation>Combes A, Hajage D, Capellier G, Demoule A, Lavou&#xe9; S, Guervilly C, Da Silva D, Zafrani L, Tirot P, Veber B, Maury E, Levy B, Cohen Y, Richard C, Kalfon P, Bouadma L, Mehdaoui H, Beduneau G, Lebreton G, Brochard L, Ferguson ND, Fan E, Slutsky AS, Brodie D, Mercat A, EOLIA Trial Group, REVA, and ECMONet Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med. 2018;378(21):1965&#x2013;1975.</Citation><ArticleIdList><ArticleId IdType="pubmed">29791822</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JP, Altman DG, G&#xf8;tzsche PC, J&#xfc;ni P, Moher D, Oxman AD, Savovic J, Schulz KF, Weeks L, Sterne JA, Cochrane Bias Methods Group. Cochrane Statistical Methods Group The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928&#x2013;d5928.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196245</ArticleId><ArticleId IdType="pubmed">22008217</ArticleId></ArticleIdList></Reference><Reference><Citation>Savovic J, Weeks L, Sterne JA, Turner L, Altman DG, Moher D, et al. Evaluation of the Cochrane Collaboration's tool for assessing the risk of bias in randomized trials: focus groups, online survey, proposed recommendations and their implementation. Syst Rev. 2014;3:37&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4022341</ArticleId><ArticleId IdType="pubmed">24731537</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth D, Heidinger B, Havel C, Herkner H. Different mortality time points in critical care trials: current practice and influence on effect estimates in meta-analyses. Crit Care Med. 2016;44(8):e737&#x2013;e741.</Citation><ArticleIdList><ArticleId IdType="pubmed">26963325</ArticleId></ArticleIdList></Reference><Reference><Citation>Chonghaile MN, Higgins BD, Costello J, Laffey JG. Hypercapnic acidosis attenuates lung injury induced by established bacterial pneumonia. Anesthesiology. 2008;109(5):837&#x2013;848.</Citation><ArticleIdList><ArticleId IdType="pubmed">18946296</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14:135&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4383202</ArticleId><ArticleId IdType="pubmed">25524443</ArticleId></ArticleIdList></Reference><Reference><Citation>R Development Core Team . R: a language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2009.</Citation></Reference><Reference><Citation>Bellani G, Laffey JG, Pham T, Fan E, Brochard L, Esteban A, Gattinoni L, van Haren F, Larsson A, McAuley DF, Ranieri M, Rubenfeld G, Thompson BT, Wrigge H, Slutsky AS, Pesenti A, LUNG SAFE Investigators. ESICM Trials Group Epidemiology, patterns of care, and mortality for patients with acute respiratory distress syndrome in intensive care units in 50 countries. JAMA. 2016;315(8):788&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">26903337</ArticleId></ArticleIdList></Reference><Reference><Citation>Acute Respiratory Distress Syndrome Network. Brower RG, Matthay MA, Morris A, Schoenfeld D, Thompson BT, Wheeler A. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301&#x2013;1308.</Citation><ArticleIdList><ArticleId IdType="pubmed">10793162</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt M, Zogheib E, Roz&#xe9; H, Repesse X, Lebreton G, Luyt CE, et al. The PRESERVE mortality risk score and analysis of long-term outcomes after extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. Intensive Care Med. 2013;39(10):1704&#x2013;1713.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094902</ArticleId><ArticleId IdType="pubmed">23907497</ArticleId></ArticleIdList></Reference><Reference><Citation>Darmon M, Schortgen F, Leon R, Moutereau S, Mayaux J, Di Marco F, et al. Impact of mild hypoxemia on renal function and renal resistive index during mechanical ventilation. Intensive Care Med. 2009;35(6):1031&#x2013;1038.</Citation><ArticleIdList><ArticleId IdType="pubmed">19242676</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y, Parodo J, Kajikawa O, de Perrot M, Fischer S, Edwards V, et al. Injurious mechanical ventilation and end-organ epithelial cell apoptosis and organ dysfunction in an experimental model of acute respiratory distress syndrome. JAMA. 2003;289(16):2104&#x2013;2112.</Citation><ArticleIdList><ArticleId IdType="pubmed">12709468</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28259355</PMID><DateCompleted><Year>2019</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1806-907X</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>3</Issue><PubDate><Year>2017</Year><Season>May-Jun</Season></PubDate></JournalIssue><Title>Revista brasileira de anestesiologia</Title><ISOAbbreviation>Rev Bras Anestesiol</ISOAbbreviation></Journal><ArticleTitle>[Effects of the positive end-expiratory pressure increase on sublingual microcirculation in patients with acute respiratory distress syndrome].</ArticleTitle><Pagination><StartPage>278</StartPage><EndPage>283</EndPage><MedlinePgn>278-283</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bjan.2017.02.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0034-7094(17)30078-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The aim of this study was to evaluate the impact of increased positive end-expiratory pressure on the sublingual microcirculation.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Adult patients who were sedated, under mechanical ventilation, and had a diagnosis of circulatory shock and acute respiratory distress syndrome were included. The positive end-expiratory pressure level was settled to obtain a plateau pressure of 30cmH<sub>2</sub>O and then maintained at this level for 20minutes. Microcirculatory (obtained by videomicroscopy) and hemodynamic variables were collected at baseline and compared with those at the end of 20min.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Twelve patients were enrolled. Overall, the microcirculation parameters did not significantly change after increasing the positive end-expiratory pressure. However, there was considerable interindividual variability. There was a negative, moderate correlation between the changes in the De Backer score (r=-0.58, p=0.048), total vessel density (r=-0.60, p=0.039) and baseline values. The changes in total vessel density (r=0.54, p=0.07) and perfused vessel density (r=0.52, p=0.08) trended toward correlating with the changes in the mean arterial pressure.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Overall, the microcirculation parameters did not significantly change after increasing the positive end-expiratory pressure. However, at individual level, such response was heterogeneous. The changes in the microcirculation parameters could be correlated with the baseline values and changes in the mean arterial pressure.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Sociedade Brasileira de Anestesiologia. Publicado por Elsevier Editora Ltda. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nunes</LastName><ForeName>Nathaly Fonseca</ForeName><Initials>NF</Initials><AffiliationInfo><Affiliation>Universidade Federal de S&#xe3;o Paulo (Unifesp), Hospital de S&#xe3;o Paulo, Disciplina de Anestesiologia, Dor e Terapia Intensiva, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bafi</LastName><ForeName>Ant&#xf4;nio Tonete</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Universidade Federal de S&#xe3;o Paulo (Unifesp), Hospital de S&#xe3;o Paulo, Disciplina de Anestesiologia, Dor e Terapia Intensiva, S&#xe3;o Paulo, SP, Brasil. Electronic address: tonybafi@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pacheco</LastName><ForeName>Eduardo Souza</ForeName><Initials>ES</Initials><AffiliationInfo><Affiliation>Universidade Federal de S&#xe3;o Paulo (Unifesp), Hospital de S&#xe3;o Paulo, Disciplina de Anestesiologia, Dor e Terapia Intensiva, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azevedo</LastName><ForeName>Luciano Cesar Pontes de</ForeName><Initials>LCP</Initials><AffiliationInfo><Affiliation>Universidade Federal de S&#xe3;o Paulo (Unifesp), Hospital de S&#xe3;o Paulo, Disciplina de Anestesiologia, Dor e Terapia Intensiva, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machado</LastName><ForeName>Flavia Ribeiro</ForeName><Initials>FR</Initials><AffiliationInfo><Affiliation>Universidade Federal de S&#xe3;o Paulo (Unifesp), Hospital de S&#xe3;o Paulo, Disciplina de Anestesiologia, Dor e Terapia Intensiva, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freitas</LastName><ForeName>Fl&#xe1;vio Geraldo Rezende</ForeName><Initials>FGR</Initials><AffiliationInfo><Affiliation>Universidade Federal de S&#xe3;o Paulo (Unifesp), Hospital de S&#xe3;o Paulo, Disciplina de Anestesiologia, Dor e Terapia Intensiva, S&#xe3;o Paulo, SP, Brasil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>por</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Efeitos do aumento de press&#xe3;o positiva ao final da expira&#xe7;&#xe3;o sobre a microcircula&#xe7;&#xe3;o sublingual em pacientes com s&#xed;ndrome do desconforto respirat&#xf3;rio agudo.</VernacularTitle><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Rev Bras Anestesiol</MedlineTA><NlmUniqueID>0401316</NlmUniqueID><ISSNLinking>0034-7094</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008833" MajorTopicYN="Y">Microcirculation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009060" MajorTopicYN="N">Mouth Floor</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011175" MajorTopicYN="Y">Positive-Pressure Respiration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adult respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">Choque</Keyword><Keyword MajorTopicYN="N">Hemodin&#xe2;mica</Keyword><Keyword MajorTopicYN="N">Hemodynamics</Keyword><Keyword MajorTopicYN="N">Mechanical ventilators</Keyword><Keyword MajorTopicYN="N">Microcirculation</Keyword><Keyword MajorTopicYN="N">Microcircula&#xe7;&#xe3;o</Keyword><Keyword MajorTopicYN="N">Positive end&#x2010;expiratory pressure</Keyword><Keyword MajorTopicYN="N">Press&#xe3;o positiva expirat&#xf3;ria final</Keyword><Keyword MajorTopicYN="N">Shock</Keyword><Keyword MajorTopicYN="N">S&#xed;ndrome do desconforto respirat&#xf3;rio do adulto</Keyword><Keyword MajorTopicYN="N">Ventiladores mec&#xe2;nicos</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>5</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>10</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>4</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28259355</ArticleId><ArticleId IdType="doi">10.1016/j.bjan.2017.02.002</ArticleId><ArticleId IdType="pii">S0034-7094(17)30078-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>